Soleno Therapeutics, Inc. (SLNO) NASDAQ
52.78
+0.21(+0.40%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
52.78
+0.21(+0.40%)
Currency In USD
Address
203 Redwood Shores Parkway
Redwood City, CA 94065
United States of America (the)
Phone
650 213 8444
Website
Sector
Healthcare
Industry
Biotechnology
Employees
115
First IPO Date
November 13, 2014
| Name | Title | Pay | Year Born |
| Anish Bhatnagar | Chairman, President, Chief Executive Officer & Chief Operating Officer | 1.05M | 1970 |
| Kristen Yen | Senior Vice President of Global Clinical Operations and Patient Advocacy | 317,190 | 1969 |
| Patricia C. Hirano | Senior Vice President of Regulatory Affairs | 515,813 | 1966 |
| Meredith Manning | Chief Commercial Officer | 605,161 | 1972 |
| James H. MacKaness | Chief Financial Officer & Compliance Officer | 656,200 | 1964 |
| Michael Huang | Senior Vice President of Clinical Development | 0 | 1974 |
| Mitchell Nagao | Senior Vice President of Medical Affairs | 0 | N/A |
| Neil Cowen | Senior Vice President of Drug Development | 0 | N/A |
| Jesse Schumaker | General Counsel | 0 | N/A |
| Lauren Budesheim | Senior Vice President of People | 0 | N/A |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.